SecBot SecBot

ONC drug pipeline

BeOne Medicines Ltd. · 3 rated drugs
$416.54
+0.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.8%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
2
0 with results posted

Upcoming catalysts

2 dated
  1. Nov 2026
    Sonrotoclax
    Phase 2 primary completion
  2. Dec 31, 2026
    Zanubrutinib
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1
Time to marketBG-C477 is in Phase 1 clinical development with no pivotal trial yet initiated. Even with an accelerated path, a potential approval would be several years away, likely 2029 or later.

BG-C477 anti-ceacam5 antibody-drug conjugate bg-c477 Updated Nov 7

What to watch

The next meaningful catalyst for BG-C477 will be further Phase 1b data, potentially at a major medical congress in 2027 (e.g., ASCO or ESMO), or an announcement of a Phase 2/pivotal trial initiation. Investors should watch for whether BeOne discloses a registrational path and timeline. The competitive landscape is also key: Merck KGaA's Precem-TcT is already in Phase 3, so BG-C477 needs to show differentiation in efficacy, safety, or target indications to carve out a commercial niche.

Bull case
  • At ESMO 2026, BG-C477 showed a 60.0% confirmed objective response rate (95% CI, 38.7-78.9) in CEA-high NSCLC patients (n=25) with a disease control rate of 92.0%, which is strong for a heavily pretreated population (median 3 prior lines of therapy).
  • The safety profile appears favorable with no grade 3 or higher interstitial lung disease or ocular events, differentiating it from some other ADCs.
  • BG-C477 is BeOne Medicines' first internally discovered ADC to achieve proof-of-concept, validating the company's internal ADC platform and potentially supporting a pipeline beyond this single asset.
Bear case
  • BG-C477 is still in early Phase 1 development with only 43 NSCLC patients reported; efficacy and durability data are preliminary and may not hold up in larger, more rigorous trials.
  • The CEACAM5 ADC space is increasingly competitive: Merck KGaA's precemtabart tocentecan (Precem-TcT) is already in Phase 3 for colorectal cancer, and M9140 (also Merck) is in Phase 1, both with similar TOP1i payload mechanisms.
  • BeOne Medicines is a large, diversified oncology company (35+ clinical and commercial assets) where BG-C477 represents a small, early-stage part of the pipeline; even positive data may have limited impact on the stock.
● neutral
Impact
PhasePhase 1
Time to marketBGB-58067 is in Phase 1 testing with no pivotal trial started. Assuming successful Phase 1b results lead to a Phase 2/3 program, potential approval is likely several years away (2029 or later under an accelerated path).

BGB 58067 bgb-58067 Updated Nov 7

What to watch

BGB-58067's ESMO 2026 data is already public and priced in. The next meaningful catalyst will be Phase 1b combination-cohort data or a decision to advance to a registrational trial, neither of which has a confirmed date. For a company as diversified as BeOne, this single early-stage asset is unlikely to drive large stock moves on its own. Watch for combination data in 1L NSCLC and PDAC, and for any partnership or out-licensing moves in the PRMT5 space that could validate the asset.

Bull case
  • Phase 1a data showed a 25.3% confirmed ORR in MTAP-deficient NSCLC (38.5% in EGFR wild-type), which is competitive for heavily pretreated patients in a biomarker-selected population
  • The drug is brain-penetrant with a 30.8% intracranial response rate in patients with baseline brain metastases, a key differentiator versus competitors like AMG 193 and MRTX1719
  • Favorable safety profile with manageable tolerability, supporting ongoing combination cohorts with standard-of-care therapies in 1L NSCLC and PDAC
Bear case
  • Still early Phase 1 with no pivotal trial started; clinical failure risk remains high and the path to approval is several years away
  • The MTA-cooperative PRMT5 inhibitor space is crowded with competitors including Amgen (AMG 193), BMS (MRTX1719), and Tango Therapeutics (TNG908/TNG462), all at similar or more advanced stages
  • BGB-58067 is one of several priority programs at a large, diversified company (market cap ~$43.5B), so even positive data may have limited impact on the stock
● neutral
Impact
PhasePhase 1
Time to marketAt least 4-6 years away, assuming successful Phase 1-3 development and regulatory filing. The Phase 1 trial is not expected to complete until September 2028, and the drug has not yet entered Phase 2 or Phase 3 testing.

BG-85738 Updated Nov 7

What to watch

No hard, dated catalyst for BG-85738 is expected in the next 12 months. The Phase 1 trial is actively recruiting with estimated primary completion in September 2028. Investors should monitor for any early safety/efficacy data presentations at medical conferences (e.g., ASCO, ESMO, AACR) which could provide early signals, but the drug is a very small component of BeOne's overall value. The key near-term drivers for ONC stock remain BRUKINSA sales trajectory and later-stage pipeline readouts, not BG-85738.

Bull case
  • Preclinical data suggest BG-85738 may be a best-in-class pan-RAS inhibitor: 1 mg/kg showed comparable antitumor efficacy to 25 mg/kg of the now-approved competitor daraxonrasib (RMC-6236) in KRAS G12V mouse models, per Chinese biotech media reports citing company data.
  • BG-85738 demonstrated blood-brain barrier penetration in preclinical models (mouse Kpuu of 39%), which could be a meaningful differentiation versus competitors if confirmed in humans, potentially opening CNS metastasis indications.
  • The pan-RAS (ON) inhibitor class has clinical proof of concept: Revolution Medicines' daraxonrasib (RMC-6236) was FDA approved on August 26, 2026 for metastatic pancreatic cancer, validating the mechanism and creating a large addressable market.
Bear case
  • BG-85738 is in very early Phase 1 testing with no human efficacy or safety data yet. Most oncology drugs that enter Phase 1 fail to reach approval, and the high failure rate for novel mechanisms is well documented.
  • The competitive landscape is rapidly evolving: Revolution Medicines' daraxonrasib (RMC-6236) was FDA approved in August 2026, and multiple other pan-RAS inhibitors from large pharma and biotech are in development, creating a crowded field by the time BG-85738 could reach market.
  • BG-85738 is a tiny component of BeOne Medicines' value. The company has a ~$46B market cap, multiple approved drugs (BRUKINSA generating over $1B quarterly in the US alone), and a broad pipeline of over a dozen clinical-stage programs. Even a successful Phase 1 readout would have minimal impact on the stock.

Other drugs in filings and trials

no drug report yet
  • BEQALZI Last: Accelerated approval · May 13, 2026
  • BRUKINSA Last: Orphan drug designation · Jan 1, 2026

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
May 13, 2026BEQALZIAccelerated approval−3.3%−2.0%
Jan 1, 2026BRUKINSAOrphan drug designation+2.4%+5.5%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ZanubrutinibA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibPhase 3Active not recruiting955Dec 31, 2026
SonrotoclaxA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaPhase 2Active not recruiting94Nov 2026
TislelizumabStudy of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPhase 3Completed404May 23, 2026